ERBB2 and breast cancer: Neoadjuvant therapy is the main therapeutic strategy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients; it can downsize the lesion for surgery, provide information on treatment response and prognosis and help to adjust follow-up treatment strategies to promote survival in non-pathological complete response (non-pCR) patients [1].